{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m didanosine
to a specific field?
Status:
US Previously Marketed
Source:
Pyrogallol U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
Source:
Phenyl Salicylate U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Phenyl Salicylate U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Phenyl salicylate belongs to the family of hydroxybenzoic acid derivatives. Phenyl salicylate is used as a food additive. Antimycobacterial activity of phenyl salicylates (salols) was studied in connection with antituberculotic activity of salicylic derivatives. Phenyl salicylates are esters. Phenyl salicylates (salols) represent a new group of antimycobacterial compounds. Phenyl salicylate is included in the number of medications, indicated for the treatment of symptoms of irritative voiding, used to relieve the discomfort, pain, frequent urge to urinate, and cramps/spasms of the urinary tract caused by an infection or a medical procedure. Phenyl salicylate works as a pain reliever in these combinations.
Status:
US Previously Marketed
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Thymol, a monoterpene, obtained from thyme oil or other volatile oils, is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions to help reduce and prevent plaque and gingivitis. Recently was shown, that this substance was able to significantly reduce the oxidative stress associated with cataract. The results suggested that thymol might be a potential therapeutic approach in the prevention of diabetic complications through its aldose reductase enzyme inhibitory and antioxidant activities.
Status:
US Previously Marketed
Source:
Betanaphthol U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
BETANAPHTHOL (or 2-Naphthol) is used as a preservative. It is known, that this compound can cause dermatitis.
Status:
US Previously Marketed
First marketed in 1912
Class (Stereo):
CHEMICAL (ACHIRAL)
Neoarsphenamine and related compounds are sulfhydryl-binding agents which are tolerated by man. A large experience in the employment of this drug and its toxic manifestations exists as a result of its former use as an antisyphilitic agent. Tertiary syphilis was a common cause for mental health conditions. Also known as Neosalvarsan, it superseded Salvarsan due to its lower toxicity. Both arsenicals still carried significant risk of side-effects and were themselves replaced by penicillin in the 1940s. Neoarsphenamine was also used for the treatment of amebic dysentery.
Status:
US Previously Marketed
Source:
Phenylcinchoninic Acid U.S.P.
(1921)
Source URL:
First marketed in 1908
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Cinchophen, phenylcinchoninic acid, seems to have been discovered in 1887 by Doebner and Gieseke and to have been introduced into medicine under the trade name of atophan in 1908 by Nicolaier and Dohrn. Since that time it has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types. Use of Cinchophen in humans ceased in the 1930s due to the discovery that it can cause serious liver damage.
Status:
US Previously Marketed
First marketed in 1907
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tricaine (MS-222, Tricaine-S), a water-soluble local anesthetic, is used commonly for sedation, immobilization, and anesthesia of poikilothermic animals and has been accepted as a common anesthetic for use in the cold-blooded animals. It has long been recognized as a valuable tool for the proper handling of these animals during manual spawning (fish stripping), weighing, measuring, marking, surgical operations, transport, photography, and research. Tricaine was developed by Merck as a sulfonated analog of benzocaine with high solubility in water. The main advantage of Tricaine is the short duration of action and rapid metabolism. There are many reports describing the use of Tricaine for anesthetizing poikilothermic animals because it is a safe agent for immersion anesthesia even though the other anesthetics such as ether, ethanol, thiopental, halothane, isoflurane, barbiturates also could be used. Amphibians could be anesthetized easily by immersion methods with Tricaine because the amphibian skin is extremely permeable and water is absorbed through the skin rather than ingested. Tricaine has been administered as an injectable agent also.
Status:
US Previously Marketed
Source:
Veronal by Friedr. Bayer 8: Co., Elberfeld, Germany, and E. Merck, Darmstadt, Germany.
(1903)
Source URL:
First marketed in 1903
Source:
Veronal by Friedr. Bayer 8: Co., Elberfeld, Germany, and E. Merck, Darmstadt, Germany.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
Status:
US Previously Marketed
Source:
Orthoform-New by Meister, Lucius, Bruening, Hoechst A. M., Germany (Victor Koechl & Co., New York)
(1896)
Source URL:
First marketed in 1896
Source:
Orthoform-New by Meister, Lucius, Bruening, Hoechst A. M., Germany (Victor Koechl & Co., New York)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
First marketed in 1883
Class (Stereo):
CHEMICAL (ACHIRAL)
